Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

Journal of Medical Virology

Volumn 78, Issue 7, 2006, Pages 954-963

  Ichinohe, Takeshi ^a,b   Watanabe, Izumi ^a,b   Tao, Eriko ^a   Ito, Satoshi ^a,b   Kawaguchi, Akira ^a,b   Tamura, Shin Ichi ^a   Takahashi, Hidehiro ^a   Sawa, Hirofumi ^c   Moriyama, Masami ^d   Chiba, Joe ^b   Komase, Katsuhiro ^e   Suzuki, Yujiro ^e   Kurata, Takeshi ^a   Sata, Tetsutaro ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e KITASATO INSTITUTE   (Japan)

Author keywords

IgA; Influenza; Nasal vaccine; Natural adjuvant; Surf clams

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; SURF CLAM MICROPARTICLE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CLAM; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; LUNG INFECTION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BIVALVIA; BRAIN; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SAFETY; STOMACH; T-LYMPHOCYTES; VACCINES, INACTIVATED;

MACTRIDAE; ORTHOMYXOVIRIDAE; PSEUDOCARDIUM SACHALINENSIS;

EID: 33744962885     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20647     Document Type: Article

References (34)

1. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S. 2002. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168:2930-2938.
2. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, Sutton P, Rockman S, Pearse M. 2003. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21:946-949.
3. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD, Jr., Lease GO. 1964. Comparisons of serologic and febrile responses in humans to vaccination with influenza a viruses or their hemagglutinins. J Lab Clin Med 63:5-13.
4. Hagiwara Y, Komase K, Chen Z, Matsuo K, Suzuki Y, Aizawa C, Kurata T, Tamura S. 1999. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine 17:2918-2926.
5. Hagiwara Y, Iwasaki T, Asanuma H, Sato Y, Sata T, Aizawa C, Kurata T, Tamura S. 2001. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine 19:1652-1660.
6. Hasegawa H, Kadowaki S, Takahashi H, Iwasaki T, Tamura S, Kurata T. 2000. Protection against influenza virus infection by nasal vaccination in advance of sublethal irradiation. Vaccine 18:2560-2565.
7. Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T. 2005. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol 75:130-136.
8. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910-2919.
9. Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. 1999. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17:1905-1909.
10. Komase K, Tamura S, Matsuo K, Watanabe K, Hattori N, Odaka A, Suzuki Y, Kurata T, Aizawa C. 1998. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine 16:248-254.
11. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903.
12. Phelan MA, Mayner RE, Bucher DJ, Ennis FA. 1980. Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand 8:233-242.
13. Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB. 2002. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110:662-672.
14. Scheicher C, Mehlig M, Dienes HP, Reske K. 1995. Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol 25:1566-1572.
15. Sever JL. 1962. Application of a microtechnique to viral serological investigations. J Immunol 88:320-329.
16. Smidt MH, Stroink H, Bruinenberg JF, Peeters M. 2004. Encephalopathy associated with influenza A. Eur J Paediatr Neurol 8:257-260.
17. Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S, Odagiri T, Tashiro M, Yoshikura H, Takemori T, Tsunetsugu-Yokota Y. 2004. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 16:1423-1430.
18. Tamura S, Kurata T. 1997. Mucosal immune responses against influenza virus. Nippon Rinsho 55:2725-2731.
19. Tamura SI, Kurata T. 2000. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn J Infect Dis 53:98-106.
20. Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. 1988. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6:409-413.
21. Tamura S, Kurata H, Funato H, Nagamine T, Aizawa C, Kurata T. 1989a. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine 7:314-320.
22. Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, Kurata T. 1989b. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine 7:257-262.
23. Tamura S, Ito Y, Asanuma H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 149:981-988.
24. Tamura S, Asanuma H, Tomita T, Komase K, Kawahara K, Danbara H, Hattori N, Watanabe K, Suzuki Y, Nagamine T, et al. 1994. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12:1083-1089.
25. Tamura S, Ishihara K, Miyata K, Aizawa C, Kurata T. 1995. Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin. Vaccine 13:339-341.
26. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, Suzuki Y, Aizawa C, Kurata T. 1996. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156:3892-3900.
27. Tamura S, Iwasaki T, Thompson AH, Asanuma H, Chen Z, Suzuki Y, Aizawa C, Kurata T. 1998. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 79:291-299.
28. Tobita K. 1975. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol (Berl) 162:23-27.
29. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol (Berl) 162:9-14.
30. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. 2000. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778-4782.
31. Wada N. 2004. Influenza-associated encephalopathy. Nippon Rinsho 62:456-461.
32. Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C, Kiyono H, Takeda Y, McGhee JR, Chiba J, Sata T, Kurata T, Tamura S. 2002. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20:3443-3455.
33. Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2003. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21:4532-4538.
34. Yetter RA, Lehrer S, Ramphal R, Small PA, Jr. 1980. Outcome of influenza infection: Effect of site of initial infection and heterotypic immunity. Infect Immun 29:654-662.